Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Jan 30, 2024

SELL
$12.46 - $29.95 $6,616 - $15,903
-531 Reduced 76.62%
162 $4,000
Q3 2023

Oct 26, 2023

BUY
$14.09 - $19.87 $9,764 - $13,769
693 New
693 $10,000
Q1 2022

May 02, 2022

SELL
$4.26 - $7.48 $10,492 - $18,423
-2,463 Closed
0 $0
Q4 2021

Jan 25, 2022

BUY
$4.75 - $7.5 $11,699 - $18,472
2,463 New
2,463 $18,000

Others Institutions Holding IMGN

About ImmunoGen, Inc.


  • Ticker IMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 220,712,992
  • Description
  • ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...
More about IMGN
Track This Portfolio

Track Macroview Investment Management LLC Portfolio

Follow Macroview Investment Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Macroview Investment Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Macroview Investment Management LLC with notifications on news.